Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.This is an entirely free service. No payments are to be made.
Here is the latest stock price and chart of Glenmark Pharma. For more details, see the Glenmark Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
|Live BSE Quotes||Feb 23, 2017 (Close)|
|Price (Rs)934.05||Open (Rs) 938.90||High (Rs) 950.00||Low (Rs) 925.25|
|% Change-1.11||Volume 16,563||Value (Rs) 15,571,167||52-Week H/L 993.00 / 715.80|
|Live NSE Quotes||Feb 23, 2017 (Close)|
|Price (Rs)933.45||Open (Rs) 940.00||High (Rs) 950.00||Low (Rs) 926.20|
|% Change-1.00||Volume 796,222||Value (Rs) 745,814,521||52-Week H/L 994.00 / 715.45|
|EPS (Rs)* 40.51||P/E Ratio (x) 23.06||Market Cap (Rs m) 253,389.08||P/BV (x) 5.93|
|*Trailing 12 months earnings, excluding extraordinary / exceptional items.||BSE Sensex | CNX Nifty|
|Glenmark Pharma Share Price Chart (Rs) - 1 Year|
Quote & Graph
S&P BSE SENSEX
Stock markets in India witnessed selling pressure in final hour of trade to finish flat amid mixed global markets. At the closing bell, the BSE Sensex stood higher by 28 points, while the NSE Nifty finished up by 13 points.
Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.
Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.
Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.
Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.
Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.More Views on News
A wealth-building strategy is more than just about how to pick good stocks.
Apurva closed a trade with gains of 18.24% for his Swing Trader subscribers. But he's not happy about it. Find out why.
Why buybacks may not always be a tempting proposition.
The investors are writing down their investments in these firms.
Will the proposed buyback change the fortunes of TCS?More